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Purpose: Magnetic resonance imaging-guided transurethral ultrasound ablation
uses directional thermal ultrasound under magnetic resonance imaging ther-
mometry feedback control for prostatic ablation. We report 12-month outcomes
from a prospective multicenter trial (TACT).
Materials and Methods: A total of 115 men with favorable to intermediate risk
prostate cancer across 13 centers were treated with whole gland ablation sparing
the urethra and apical sphincter. The co-primary 12-month endpoints were
safety and efficacy.
Results: In all, 72 (63%) had grade group 2 and 77 (67%) had NCCN intermediate
risk disease. Median treatment delivery time was 51 minutes with 98% (IQR 95e99)
thermal coverage of target volume and spatial ablation precision of 1.4 mm on
magnetic resonance imaging thermometry. Grade 3 adverse events occurred in 9
(8%) men. The primary endpoint (U.S. Food and Drug Administration mandated) of
prostate specific antigen reduction 75% was achieved in 110 of 115 (96%) with
median prostate specific antigen reduction of 95% and nadir of 0.34 ng/ml. Median
prostate volume decreased from 37 to 3 cc. Among 68 men with pretreatment grade
group 2 disease, 52 (79%) were free of grade group 2 disease on 12-month biopsy. Of
111 men with 12-month biopsy data, 72 (65%) had no evidence of cancer. Erections
(International Index of Erectile Function question 2 score 2 or greater) were
maintained/regained in 69 of 92 (75%). Multivariate predictors of persistent grade
group 2 at 12 months included intraprostatic calcifications at screening, suboptimal
magnetic resonance imaging thermal coverage of target volume and a PI-RADS
3 or greater lesion at 12-month magnetic resonance imaging (p <0.05).
Conclusions: The TACT study of magnetic resonance imaging-guided tran-
surethral ultrasound whole gland ablation in men with localized prostate cancer
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demonstrated effective tissue ablation and prostate specific antigen reduction with low rates of toxicity and
residual disease.
Key Words: prostatic neoplasms; radiotherapy, image guided; minimally invasive surgical procedures;
transurethral resection of prostate; magnetic resonance imaging
MEN with early stage prostate cancer are faced with a
choice between active surveillance or radical therapy
(surgery or radiation). Emerging image-guided mini-
mally invasive ablative treatments offer an appealing
alternative with potential benefits of a relatively
nonmorbid intervention and cancer eradication.
Multiparametric magnetic resonance imaging di-
rects targeted therapy and enables real-time mapping
of tissue temperature during ablation. MRI-guided
transurethral ultrasound ablation is a novel ablation
procedure using the TULSA-PRO device, which le-
verages MRI thermometry and disease localization to
ablate via transurethral thermal ultrasound.1e8
TULSA differs from transrectal high intensity focused
ultrasound by use of a continuous sweeping directional
ultrasound beam delivered from the prostatic urethra
(rather than discrete spots transrectally), real-time
MRI for planning and thermometry, and cooling of
the urethra and rectum.
Treat-and-resect studies confirmed feasibility of
thermally ablating prostate tissue under magnetic
resonance thermometry with an accuracy of 1 to 3
mm. Heating 55C or greater achieved 100% cell kill
in the treatment zone.8,9 A phase I study of whole
gland treatment in men with predominately low
risk prostate cancer demonstrated an acceptable
safety profile and quality of life outcomes at 12
months10 but intentionally left 10% of the periph-
eral prostate untreated. The multicenter prospec-
tive trial described here evaluates the safety and
efficacy of ablating to the prostate capsule.
MATERIALS AND METHODS
Patients
TULSA-PRO Ablation Clinical Trial is a prospective,
multi-center, single-arm pivotal study in patients with
localized prostate cancer (NCT02766543). The protocol
was designed in conjunction with the U.S. Food and Drug
Administration towards 510(k) clearance as a prostate
ablation device and received IRB approval at 13 centers in
the U.S.A., Europe and Canada. Informed consent was
obtained from all participants.
Inclusion criteria were age 45 to 80 years old, Gleason
Grade Group 1 to 2 prostate cancer, clinical stage T2b or
less, PSA 15 ng/ml or less, minimum 10-core biopsy, no
previous treatment and could undergo MRI.
Exclusion criteria were prostate greater than 90 cc,
width greater than 6 cm or length greater than 5 cm;
nonMRI compatible implants, active infection, suspected
tumor within 3 mm of the prostate apical plane on MRI,
intraprostatic cysts or calcifications greater than 1 cm.
TULSA Procedure
Whole gland TULSA sparing the urethra and a 3 mm
margin of prostate tissue at the apical sphincter was per-
formed within 3T MRI (Skyra/Prisma, Siemens, Germany;
Achieva/Ingenia, Philips, Netherlands). The device consists
of a rigid ultrasound applicator which incorporates a linear
array of 10 ultrasound transducers that emit directional
(focused to a blade) energy into the prostate (fig. 1). This
results in a continuous region of thermal ablation to the
prostate capsule. Water pumped through the applicator and
an endorectal cooling device provides 1 to 2 mm of peri-
urethral and rectal preservation.10 The applicator is
secured with a MRI compatible robot that provides remote
linear and rotational motion of the device within the pros-
tatic urethra. A treatment delivery console includes software
to outline the target prostate boundary, monitors thermal
therapy and implements temperature feedback.
The TULSA outpatient procedure was performed as a
collaboration between a urologist and radiologist as previ-
ously described.8e10 Prophylactic antibiotics were adminis-
tered before and for several days after treatment. General
anesthesia, cystoscopy and suprapubic catheter placement
were performed outside the MRI suite. Treatment planning
images were acquired and used to register the ultrasound
applicator location, guide adjustments and define target
ablation area. In the context of a safety and efficacy study,
ablation plans were set with a small margin from the apical
plane to avoid incontinence. During treatment, images from
magnetic resonance thermometry are displayed every 5 to 6
seconds to determine the amount of energy delivered by each
transducer. The ultrasound frequency, applied power and
device rotation are automatically modulated to achieve an
ablative temperature of 55C within the treatment target.
Patient Assessment and Endpoints
Primary objectives were safety and efficacy. Primary safety
endpoint was frequency and severity of adverse events,
documented at each visit according to the Common Termi-
nology Criteria for Adverse Events. Primary efficacy
endpoint for prostate tissue ablation was proportion of men
achieving a PSA reduction75% of baseline, defined to meet
regulatory requirements rather than oncological control.
Secondary endpoints were: early oncological efficacy
defined as the proportion of patients with no cancer or
reduced grade and extent of cancer on 12-month 10-core
biopsy, prostate volume reduction assessed by central
radiology, patient reported changes in quality-of-life, and
evaluation of post treatment multiparametric MRI.
Urinary symptoms were assessed based on a mini-
mally important difference of 5 in the International
Prostate Symptom Score11 and a MID of 1 for the IPSS
quality of life item. MIDs for voiding and storage sub-
scores were half the standard deviation of baseline
values.12 Voiding function was assessed by the number of
men with postvoid residual less than 100 ml, and number of
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men with peak urinary flow rate 15 ml/sec or greater.
Erectile function was assessed using International Index of
Erectile Function questionnaire with a MID of 4.13 Potency
was evaluated by IIEF-15 question 2, similar to analyses in
focal therapy trials.14 Other quality of life domains, daily
pad use and urine leakage were assessed with the EPIC-50
questionnaire.15 Missing IPSS, IIEF, EPIC and ECOG
scores were not interpolated.
Statistical Methods
The predefined primary efficacy endpoint was the pro-
portion of men achieving a prostate specific antigen reduction
75% or more of baseline. With a success threshold of 50% of
patients, a 1-sided exact test (a[0.025) was expected to reach
80% power with 90 patients. For accurate estimation of safety
and secondary outcomes and to account for dropout, 110 pa-
tients were targeted.
Continuous variables describing PSA, prostate volume
and quality of life scores were summarized by median and
interquartile range and compared to baseline using paired
2-sided Wilcoxon signed rank tests or Friedman tests with
significance of p <0.05. Dichotomous variables describing
the number of patients who experienced a gain or loss of
function, or moderate change in quality of life 2 or more
times MID were summarized as proportions and
compared to baseline using exact tests.
Multivariate logistic regression assessed the relative
odds of having GG2 on 12-month biopsy, adjusting for
baseline characteristics, treatment day parameters and
12-month MRI. Analyses were performed using R (R
Foundation for Statistical Computing, Austria).
RESULTS
Patients
Among 115 men, median age was 65 (IQR 59e69)
years, PSA 6.3 (4.6e7.9) ng/ml; 77 (67%) and 38 (33%)
Figure 1. TULSA procedure. A, rendering of ultrasound applicator and endorectal cooling device. B, sagittal and coronal views of 3D T2-
weighted image of ultrasound applicator and planned ablation zone. C, ablation zone prescribed on intraoperative axial T2-weighted
images from prostate apex to base. D, MRI temperature map depicting maximum temperatures achieved during treatment.
E, enhancement defect confirms ablation extent on posttreatment contrast enhanced T1 weighted images.
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patients had NCCN intermediate and low risk dis-
ease, respectively (table 1). Seventy-two patients
(63%) had GG2 (3 had GG3 and were granted pro-
tocol deviations due to having only slightly more than
50% Gleason pattern 4 cancer with otherwise favor-
able characteristics), 26 (23%) had high volume GG1
(3 or more cores or 50% or greater in a core) and 17
(15%) had low volume GG1.
TULSA Procedure
Median procedure time from positioning the anes-
thetized patient in the MRI to recovery was 243
(IQR 201e281) minutes. Median ablation time was
51 (IQR 39e66, range 21e112) minutes. Median
targeted prostate volume was 40 (IQR 31e51) cc,
with 98% of the prescribed target prostate volume
heated to ablative temperatures (thermal dose
greater than 240 equivalent minutes at 43C)16 and
spatial accuracy/ablation precision of 0.11.4 mm
measured on MRI thermometry.
Patients were discharged the same day (55%) or
admitted overnight (45%), per protocol and physician’s
discretion. Median time to successful voiding and
removal of suprapubic catheter was 17 (IQR 11e24)
days.
Safety
A total of 12 Grade 3 (severe) adverse events occurred
in 9 (8%) men, including genitourinary infection (4%),
urethral stricture (2%), urinary retention (1.7%),
urethral calculus and pain (1%) and urinoma (1%), all
resolved by the 12-month visit (table 2). There were no
Grade 4 events, rectal injuries, severe incontinence
requiring surgical intervention or severe erectile
dysfunction unresponsive to medication.
At 12 months, 27 men (23%) had moderate ED
(Grade 2, managed by oral medication with no new
use of vacuum pump or penile injections), and 3
(2.6%) had moderate urinary incontinence (Grade 2,
pad use). The majority of other attributable Grade 1
and 2 (mild to moderate) adverse events occurred
and resolved within 3 months of treatment. Urinary
tract infections (25% Grade 2 including asymptom-
atic positive culture at 1-month urine analysis)
resolved with oral antibiotics, and 2 (1.8%) had recur-
rent infections ongoing at 12 months. Urethral stric-
ture occurred in 3 men (2.6%) and resolved with a
transurethral procedure. Urinary retention in 10 men
(9%) resolved within 3 months with medication and/or
catheterization. Moderate abdominal or rectal discom-
fort was experienced by 4men (3.5%) and resolved with
ibuprofen/acetaminophen in the first month.
Efficacy
PSA reduction 75% or greater as achieved in 110
(96%) men. Median PSA reduction was 95% (IQR
91e98) to a median nadir of 0.34 (IQR 0.12e0.56)
ng/ml. Median (IQR) PSA decreased from 6.3
(4.6e7.9) ng/ml to 0.5 (0.3e1.2) ng/ml at 1 month. At
12 months, median PSA was stable at 0.5 (0.3e1.2)
ng/ml with biochemical failure (PSA nadirD 2 ng/ml)
in 3 men (2.6%; table 3). Two of 115 patients had
missing 12-month PSA values, which were interpo-
lated from the 6-month visit.
Median decrease in perfused prostate volume as
assessed by a central radiologist using 12-month
MRI was 91%, from a median 37 (IQR 27e48) cc
to 2.8 (IQR 1.7e4.7) cc. At 12 months, 111 (97%)
men underwent prostate biopsy (fig. 2), the
remaining 4 men refused. A median of 10 (IQR
10e12) cores sampled the diminished prostate vol-
ume, for an increased sampling density of 3.5 (IQR
2.1e5.7) cores per cc of prostate compared to 0.4
(IQR 0.3e0.5) cores per cc at baseline. There was no
evidence of cancer in 72 (65%) men and 16 (14%)
Table 1. Baseline patient demographics and clinical
characteristics of 115 patients
Median age (IQR, range) 65.0 (59e69, 46e79)






No. Grade Group (%):
Low volume GG1 (2 or fewer cores and
less than 50% in any core)
17 (15)
High volume GG1 26 (23)
GG2 69 (60)
GG3 3 (3)
No. biopsy cores positive (%):
1 to 2 cores 33 (29)
3 to 4 cores 36 (31)
5 or more cores 46 (40)
No. disease laterality (%):
Unilateral GG1 28 (24)
Bilateral GG1 15 (13)
Unilateral GG2 36 (31)
GG2 with contralateral GG1 18 (16)
Bilateral GG2 18 (16)
Median PSA, ng/ml (IQR, range) 6.3 (4.6e7.9, 0.9e17.1)




T2, unspecified substage 5 (4)
No. prostate volume (%):*
Less than 20 cc (minimum 15 cc) 5 (4)
20 to 40 cc 51 (44)
40 to 60 cc 48 (42)
60 to 80 cc 7 (6)
80 cc or more (maximum 125 cc) 4 (3)
No. baseline PI-RADSTM (%):*




No. prostatic calcifications (%):
No 101 (88)
Yes (max less than 10 mm) 14 (12)
* Assessed by site
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had low volume GG1. Among the 68 men with GG2
or greater at baseline, 54 (79%) were free of GG2 or
greater at 12 months. Similarly, 20 of 26 (77%) men
with high volume GG1 at baseline had either no
cancer or low volume GG1 (fewer than 3 cores and
less than 50% per core) at 12 months. In men with
low volume GG1 at baseline, 13 of 17 (77%) were
free of any disease at 12 months. Overall, histolog-
ical improvement (eradication of GG2, shift from
high to low volume GG1, or eradication of GG1
disease) occurred in 7% to 80% of men across all risk
subgroups.
On multivariable analysis (supplementary table,
https://www.jurology.com), predictors of GG2 or
greater at 12-month biopsy included presence of
intraprostatic calcifications at screening (OR 11.4,
95% CI 1.8e73, p[0.01), failure to achieve thermal
dose coverage 96% or greater (OR 4.34, CI 1.1e18,
p[0.04) and presence of PI-RADS version 2 score 3 or
greater lesion at 12-month MRI (OR 8.79, CI 1.8e44,
p[0.008). Baseline tumor grade, bilaterality, baseline
MRI findings, prostate volume and PSA were not
associated with presence of GG2 or greater at 12-
month biopsy. Results of the model did not change
significantly upon removal of MRI after treatment or
addition of pre-treatment apical disease.
Based on 12-month assessment, 8 (7%) men
sought additional treatment, while 11 (10%) men
with GG2 or biochemical failure had thus far
refused further therapy. Repeat TULSA was not
permitted per protocol, and patients opted for
radical prostatectomy (4) or radiation (4), for which
detailed outcomes are not currently available.
Quality of Life
Patient reported measures of erectile function
(IIEF-15) and overall sexual function and satis-
faction (EPIC-50 sexual domain score) indicated an
initial decline followed by gradual recovery, with a
third experiencing moderately decreased sexual
function at 12 months (table 3). Of the 92 men who
were potent at baseline (IIEF-15 question 2 score 2
or greater indicating erection firmness sufficient
for penetration at least some of the time), 69 (75%)
maintained or regained potency by 12 months
(fig. 3).
EPIC-50 urinary incontinence domain scores
declined at 1 to 3 months and recovered to baseline
by 6 months. At 12 months, less than 1% of patients
were incontinent (more than 1 pad/day on EPIC-50
item 5), 7% wore 1 pad/day and 4% reported more
daily leakage than baseline.
Table 2.Adverse events reported according to CommonTerminology Criteria for Adverse Events as total number of attributable events
occurring at any time (and proportion of study participants experiencing those events), and subset of those events thatwere ongoing at
12-month visit.
Attributable Adverse Events
Any Occurrence Ongoing at 12 Months
Description Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
No. genitourinary (%):
Erectile dysfunction 16 (14) 33 (29) e 14 (12) 27 (23) e
Hematuria 43 (35) 2 (2) e e e e
Urinary incontinence 21 (17) 7 (6) e 9 (8) 3 (3) e
Pain/discomfort (pelvic/genital/treatment area) 21 (15) 8 (7) e 2 (2) e e
Urinary urgency 24 (18) 5 (4) e 3 (3) e e
Edema 25 (17) 4 (4) e e e e
Dysuria 13 (11) 11 (7) e 2 (2) e e
Urinary frequency 14 (12) 2 (2) e 4 (3) e e
Ejaculation disorder 12 (10) 3 (3) e 6 (5) 3 (3) e
Bladder spasm 1 (1) 12 (10) e e e e
Urethral bleeding 13 (11) e e e e e
Urethral discharge 10 (9) 1 (1) e e e e
Urinary retention e 9 (7) 2 (2) e e e
Weak urinary stream 9 (6) 4 (3) e 2 (2) 3 (3) e
Nondescriptive lower urinary tract symptoms 6 (5) 4 (3) e 3 (3) e e
Pain/discomfort (bladder/urinary tract) 4 (3) 4 (3) 1 (1) 1 (1) e e
Debris in urine 5 (3) 1 (1) e e e e
Urethral stricture e 1 (1) 2 (2) e e e
Urethral calculus e e 1 (1) e e e
Urinoma e e 1 (1) e e e
No. infections (%):
Urinary tract infection e 40 (25) 3 (3) e 2 (2) e
Epididymitis e 6 (5) 2 (1) e e e
No. gastrointestinal pain/discomfort (abdominal/anorectal) (%) 10 (9) 4 (3) e e e e
No. general pain/discomfort (hip/back) (%) 5 (3) 5 (4) e e e e
No. deep vein thrombosis (%) e 1 (1) e e e e
Grade 1 to 2 events occurring in 3% or more of patients and all serious (requiring hospital stay) or severe (grade 3) events are listed, with worst grade reported for each patient.
There were no attributable Grade 4 to 5 events. Includes 10 attributable serious adverse events (requiring hospital stay) occurring in 7 (6%) men, all resolved by 12 months:
infection (4%), urinary retention (1%), urethral stricture (1%), urinoma (1%), and deep vein thrombosis (1%).
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IPSS urinary symptom score, quality of life score
and voiding/storage subscores recovered to base-
line by 3 months and were unchanged at 12
months, with similar numbers of men experiencing
moderate improvements or declines in symptoms.
At 12 months, EPIC-50 urinary irritative/obstruc-
tive domain scores had recovered, peak urine flow
rate was unchanged and nearly all men with high
postvoid residual at baseline experienced a signif-
icant improvement. EPIC-50 bowel domain scores
and ECOG performance status recovered by the 3-
month visit.
DISCUSSION
In a large, multicenter prospective study in men
with predominately intermediate risk prostate
cancer, whole gland ablation sparing the urethra
and apical sphincter with MRI-guided transure-
thral ultrasound ablation met its primary regula-
tory endpoint of PSA reduction and had a low rate
of morbidity. At 12 months extensive biopsy sam-
pling of the markedly reduced prostate volume
demonstrated a benefit for nearly 80% of men.
TULSA also had a relatively low risk of functional
decline. No men had a rectal injury, 96% returned
to baseline urinary continence and 75% of potent
men maintained or returned to erections sufficient
for penetration.
The primary PSA endpoint was met, defined by
regulators to assess the efficacy of TULSA as a
prostate tissue ablation device. This is an early
report from a single-arm study. The patient popu-
lation allowed for evaluation of oncologically rele-
vant secondary outcomes including PSA stability,
posttreatment biopsy and salvage treatment.
Table 3. Clinical outcomes
Efficacy Outcomes
(Median and






















6.3 (4.6e7.9) 0.5 (0.3e1.2) 0.5 (0.2e0.9) 0.5 (0.2e1.0) 0.5 (0.3e1.2) e e e e e
Median prostate
volume,†, ‡ cc (IQR)




84/114 (74) e e e 31/104 (30) e e e e e




7 (3e10) 14 (7e21) 8 (4e12) 6 (2e12) 6 (3e9) 5 8/112 (7) 7/112 (6) e e
IPSS Quality of Life 1 (0e3) 3 (1e5) 2 (1e3) 1 (0e2) 1 (0e2) 1 15/113 (13) 21/113 (19) e e
IPSS Voiding Sub-
score
2 (0e6) 5 (2e10) 2 (0e5) 2 (0e6) 2 (0e6) 1.9 20/113 (18) 20/113 (18) e e
IPSS Storage Sub-
score
3 (2e6) 7 (4e11) 5 (3e7) 3 (2e7) 3 (2e5) 1.4 19/112 (17) 16/112 (14) e e
IIEF-15 Erectile
Function Domain




100 (92e100) 84 (54e100) 84 (65e100) 100 (79e100) 100 (86e100) 9 16/112 (14) 8/112 (7) e e
EPIC Irritative/
Obstructive Domain
93 (86e97) 54 (32e75) 86 (75e96) 93 (79e100) 93 (82e100) 7 9/110 (8) 6/110 (5) e e
EPIC Bowel Domain 96 (93e100) 95 (88e98) 98 (93e100) 98 (93e100) 97 (93e100) 6 6/110 (5) 2/110 (2) e e




17 (12e22) e e e 16 (12e22) e e e 7/37 (19) 7/25 (28)
Postvoid residual,kml 30 (9e67) e e e 14 (0e50) e e e 6/78 (8) 11/15 (73)
ECOG Performance
Status{ (% men)
112/114 (98) 95/110 (86) 90/94 (96) 104/107 (97) 105/107 (98) e e e 2/112 (2) 2/2 (100)
Bolded values have a statistically significant difference from baseline. MID for IPSS subscores defined as 0.5 SD from baseline.
* Nadir 0.34 (0.1e0.6); reduction 95% (91e98); proportion with PSA reduction greater than 75%: 110/115 (96%).
† Assessed by central radiology laboratory.
‡ Reduction 91% (87e96).
§ Uroflowmetry included only if voided volume 150 ml or more, reference 15 ml/s or more.
k Ref. more than 100 ml.
{ Ref. 1 or more.
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Notwithstanding the limitations of comparisons
between ablative and extirpative therapies, the 7%
rate of salvage treatment and 20% rate of residual
clinically significant prostate cancer in intermedi-
ate risk patients (two-thirds of those with GG2 or
greater having either bilateral disease or at least 5
positive cores) are in line with accepted rates of
early failure or additional intervention after stan-
dard treatments17,18 and goals for retreatment
after ablative therapies.19 The inclusion of men
with low risk disease reflects guidelines at the time
the protocol was designed. However, the majority
of these patients enrolled with suspicious MRI le-
sions and either bilateral disease or 3 or more
positive cores.
TULSA was associated with a high degree of
safety and maintenance of quality of life. Moderate
urinary incontinence (Grade 2, pads indicated) was
experienced by 2.6% of men, with 7% wearing 1 pad
per day and 1 (0.9%) wearing more than 1 pad per
day. ED was experienced by 23% to 35% while
erection sufficient for penetration was preserved in
75% of potent men. These compare favorably to
radical prostatectomy20,21 and other whole gland
ablation techniques.22,23 We did not observe any
bowel toxicity, an important concern for patients
undergoing radiation therapy or transrectal high
intensity focused ultrasound.24 An appeal of the
transurethral approach is that energy is not
directed through the rectum. Therefore, the risk of
rectal injury is less than a transrectal approach.
This also means that the entire prostate gland can
be treated, without limitations related to prostate
volume, or distance from the anterior prostate to the
rectum.
Limitations of this report include the relatively
short duration of followup and reliance on post-
ablation systematic biopsy for evaluating local
histological control. While level 1 evidence sup-
porting MRI-targeted biopsy emerged after the
Figure 2. Histological outcomes stratified by grade and volume at baseline and 12 months. Of 68 men with GG2 or greater disease on
baseline biopsy 79% experienced clinical benefit of either no cancer or only GG1 upon 12-month systematic 10-core biopsy of their
residual prostate tissue. Likewise, of 26 men with high volume GG1 (3 or more positive cores or 50% or more per core) at baseline
77% experienced the clinical benefit of either no cancer or only low volume GG1 at 12 months. Overall, 65% of 111 men who
underwent biopsy after TULSA had no evidence of cancer at 12 months.
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study was designed, the median of 10 systematic
posttreatment biopsy cores from small prostates
(median 3 cc) represents a high sampling density
compared to typical 1 core/cc saturation template
mapping biopsy25 and is unlikely to miss signif-
icant residual cancers. Thermally fixed nonviable
cells can retain their apparently malignant tis-
sue morphology, confounding Gleason grading
and potentially introducing false positives.26
This is a limitation of relying on postablation
biopsies to define oncologic outcome, analogous
to early postirradiation biopsies.27 The relation-
ship between early postTULSA outcomes and
traditional endpoints such as clinical recurrence,
need for salvage therapy or metastasis-free sur-
vival is unknown and will become available with
ongoing 5-year followup. A recent publication
indicates that salvage prostatectomy after TULSA
is safe.28
Our study represents the initial learning curve
at 13 academic sites with a first generation com-
mercial device for which experienced clinical
proctors were not yet available. The small number
of subjects at each site demonstrated the ability
for new teams to adopt the technique but was re-
flected in the overall anesthesia durations that
were long compared to the approximately 1-hour
ablation times. Outcomes may improve with more
aggressive screening for intraprostatic calcifica-
tions, re-treatment of under-heated regions based
on magnetic resonance thermometry, and further
experience. Despite excluding patients with calci-
fications greater than 1 cm, some calcifications
less than 1 cm caused acoustic shadowing and were
associated with a higher likelihood of residual GG2
or greater disease, indicating the need for more
strict limitation of calcification size in future
studies. Excluding the 14 patients with calcifica-
tions identified at screening, GG2 disease was
eliminated in 51 of 60 (85%) men. Early indicators
of residual disease such as inadequate thermal
coverage on intraoperative maps (observed in 33
patients, of whom 27% had residual GG2), inap-
propriate PSA response, or suspicious lesion on
postTULSA MRI may identify men who might
benefit from more rigorous followup or a repeat
procedure. Since completion of this study, TULSA
has been used primarily for customized partial
gland ablation with urethral rather than supra-
pubic catheterization.29,30 This has decreased the
relatively long posttreatment catheterization
period and is likely to reduce the likelihood of
urinary complications, ED, incontinence and in-
fections. The data in this study are significantly
improved compared to the phase 1 study10 sug-
gesting that algorithm modifications and local
experience improves the efficacy and safety of
TULSA.
CONCLUSIONS
TULSA is a minimally invasive procedure that
employs planar ultrasound energy with customized
MRI based treatment planning, real-time thermal
dosimetry and closed loop temperature feedback
control for effective prostate cancer ablation with a
favorable side effect profile and minimal impact on
quality of life. Further studies are warranted and
ongoing.
Figure 3. Functional outcomes. Erection sufficient for penetration (IIEF question 2 score 2 or greater) assessed among 92 men who had
adequate function at baseline. Urinary continence reported as normalized proportion of patients free of daily leakage or pad use defined
using EPIC questions 1 and 5, respectively.
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EDITORIAL COMMENTS
The authors, an impressive group of experienced
clinician-scientists, evaluated a relatively new de-
vice to treat early stage prostate cancer using MRI
guided transurethral ultrasound ablation (TULSA).
The protocol was designed to gain U.S. Food and
Drug Administration 510(k) clearance as a prostate
tissue ablation device. A more vigorous trial will be
necessary to gain clearance as a device to specif-
ically treat prostate cancer, a goal of a variety of
devices.
The study was comprised of 115 men recruited
from 13 centers. Although 63% had GG2 cancers it
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is important to note that GG2 alone may add very
limited risk. The cut point for high volume disease
may easily be exceeded with systematic and tar-
geted biopsy. It appears that the study population
was carefully selected and represented a generally
lower risk population. The fact that PI-RADS 3 or
greater predicted residual disease supports this
notion.
Although the device described uses a transure-
thral approach, patients underwent general anes-
thesia (243 minutes) and had a suprapubic catheter
placed (17 days). Treatment was delivered in a MRI
unit and was directed by both a urologist and a
radiologist. Other devices may have advantages
when judged by these criteria. The authors mention
that focal therapy is possible with this device and it
is likely that this will be pursued, a similar path
compared to other ablation strategies which started
out as whole gland treatments.
In summary, the authors are to be congratulated
for a well-done initial study of a new approach to
prostate tissue ablation. How it will compare to the
long list of competing approaches remains to be
seen. When evaluating all such approaches, urolo-
gists have to commit to careful patient selection
(avoiding treatment of men who may need no
treatment) and designing and completing random-
ized trials that more critically assess their value in
cancer control and avoidance of morbidity.1
Peter R. Carroll
Department of Urology
University of California, San Francisco
San Francisco, California
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Klotz et al present 12-month data on 115 men with
low intermediate risk prostate cancer undergoing
transurethral ultrasound ablation (TULSA) in 13
centres. This novel minimally invasive procedure
applies energy using a rotational device placed in
the prostatic urethra (reference 10 in article). Real
time thermal dosimetry aims for whole gland abla-
tion up to the capsula at around 55C while a water
cooling system spares urethra and rectum. The
treatment is given under anesthesia with the pa-
tient in the magnetic resonance imaging (MRI)
scanner (median total procedure 243 minutes;
ablation time only 51 minutes).
Main endpoints were established in collaboration
with the U.S. Food and Drug Administration. Grade
3 adverse events were seen in 8%. Of preprocedure
potent men, many (75%) maintained or regained
potency by 12 months. Incontinence rates were also
very favorable. The mandated endpoint of greater
than 75% prostate specific antigen (PSA) reduction
was reached in 96%. Biochemical failure was seen in
only 3%. In 35% however cancer was still found in
followup biopsies after 1 year. Long-term oncolog-
ical endpoints were not the objective of this trial.
As applicable to many novel ablative (focal)
therapies,1 many questions remain including posi-
tion of TULSA between active surveillance or
radical therapies; learning curve; patient-selection
using MRI and targeted/systematic biopsies; fol-
lowup regimen of small remaining gland using
posttreatment low PSA, MRI, and/or biopsies; indi-
cation for and complications and oncological out-
comes of re-intervention or salvage therapy
(reference 28 in article). Still, TULSA may prove to
be a valuable addition to our treatment arsenal,
providing cancer control with low toxicity. Pro-
spective analysis from properly conducted studies
and open presentation of the results of all these new
techniques should be encouraged.








1. van der Poel HG, van den Bergh RCN, Briers E et al: Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018. Eur Urol
2018; 74: 84.
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REPLY BY AUTHORS
We agree with the comments expressed in these
editorials. Our publication represents an early
experience (incorporating the learning curve) with
this novel technology. It reports endpoints
mandated by the U.S. Food and Drug Administra-
tion (FDA) geared toward regulatory approval. Pa-
tient selection was designed pragmatically to
enhance study accrual. Ultimately, we believe the
primary role for this technology will be hemi-
ablation for patients with unilateral intermediate
risk cancers not interested in active surveillance.
We agree with Drs. van den Bergh and Vis that
many questions about the role and limitations of
focal therapy remain, including patient selection,
systematic vs targeted biopsies, followup strategies
and success of retreatment/salvage therapies.
Ongoing trials and the incipient international reg-
istry of focal therapy outcomes (Focal Therapy So-
ciety) will help answer these important questions.
Dr. Carroll comments that FDA approval was for
ablation and not prostate cancer treatment. No de-
vice has received FDA approval for prostate cancer
treatment since the Medical Device Regulation Act
of 1976. Pre-1976 treatments such as radiation,
prostatectomy and cryotherapy were all grand-
fathered. Robotic surgical devices have also not
received FDA indication to treat cancer. For
example, “the FDA’s evaluation of robotically-
assisted surgical devices has generally focused on
determining whether the complication rate at 30
days is clinically comparable to other surgical
techniques. for use in the prevention or treatment
of cancer, the FDA anticipates these uses would be
supported by specific clinical outcomes, such as local
cancer recurrence, disease-free survival, or overall
survival.”1 Therefore, TULSA for tissue ablation is
in a similar regulatory position as the Da Vinci
robot.
The conceptual appeal of TULSA is the modifi-
able closed loop system, whereby energy delivered
can be tailored based on the anatomical tempera-
ture map. Our data suggest functional outcome and
elimination of high grade cancer are promising.
With increased experience, iterative selection and
treatment modifications, and requisite longer-term
followup, we anticipate that TULSA will have a
place in the treatment landscape for localized
prostate cancer.
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